All In Biotech

Drug Trial Radar · NCT07735767

Tdap Vaccination During Pregnancy or Postpartum and Lactation-Related Outcomes

Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36,245

Actual

Start

Jan 2014

Primary completion

Dec 2022

Study completion Dec 2022

Sponsor

Lead sponsor
HealthPartners InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sanofi; Kaiser Permanente
First posted
Jul 30, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Female only, from 16 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A retrospective cohort study based on the secondary use of pre-existing data. The study assesses the association between antenatal and postpartum maternal Tdap vaccination and select infant and lactation-related outcomes.

Conditions

  • Pertussis Vaccines

Interventions

  • Tetanus Toxoid, acellular pertussis, diphtheria toxoidBiological

    No investigational vaccines will be administered in this study. Participants will be included in the study on the basis of their having received Tdap vaccine as part of routine care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Infant growth - failure to thrive (Subgroup Pregnancy)Time frame: 3 months (91 days) to 12 months of age
  2. Infant growth - failure to thrive (Subgroup Postpartum)Time frame: 3 months (91 days) to 12 months of age
  3. Infant health care utilization - Number of infant outpatient visits up to 6 months of age (Subgroup Pregnancy)Time frame: 0 to 6 months after delivery
  4. Infant health care utilization - Number of infant outpatient visits in the 90 days after index date (Subgroup Postpartum )Time frame: up to 6 months: 90-day window for vaccination plus 90-day window for outcome assessment
  5. Infant health care utilization - Number of infant emergency department visits up to 6 months of age (Subgroup Pregnancy)Time frame: 0 to 6 months after delivery
  6. Infant health care utilization - Number of infant emergency department visits in 90 days after index date (Subgroup Postpartum)Time frame: Up to 6 months: 90-day window for vaccination plus 90-day window for outcome assessment.
  7. Human milk feeding initiation vs no initiation (Subgroup Pregnancy)Time frame: 0 to 12 months
  8. Any human milk feeding vs none around the 2-month Well Child Visit (WCV) (Subgroup Pregnancy)Time frame: 42 to 104 days after delivery
  9. Any human milk feeding vs none around the 2-month WCV (Subgroup Postpartum)Time frame: 42 to 104 days after delivery
  10. Exclusive human milk feeding vs none around the 2-month WCV (Subgroup Pregnancy)Time frame: 42 to 104 days after delivery
  11. Exclusive human milk feeding vs none around the 2-month WCV (Subgroup Postpartum)Time frame: 42 to 104 days after delivery
  12. Any human milk feeding vs none around the 6-month WCV (Subgroup Pregnancy)Time frame: 148 to 210 days after delivery
  13. Any human milk feeding vs none around the 6-month WCV (Subgroup Postpartum)Time frame: 148 to 210 days after delivery
  14. Exclusive human milk feeding vs none around the 6-month WCV (Subgroup Pregnancy)Time frame: 148 to 210 days after delivery
  15. Exclusive human milk feeding vs none around the 6-month WCV (Subgroup Postpartum)Time frame: 148 to 210 days after delivery

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.